Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M701 in Malignant Pleural Effusions Caused by NSCLC
NCT05543330Phase 2Recruiting
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Sep 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of M701 in malignant pleural effusion (MPE), non-small cell lung cancer (NSCLC), sponsored by Wuhan YZY Biopharma Co., Ltd.. Started Sep 2022; status: recruiting.
02
Drugs
M701
03
Conditions
malignant pleural effusion (MPE)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05543330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05543330.